Karen A. Gammeltoft
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots.
Journal: Emerging microbes & infections
Published: October 15, 2025
PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2.
Journal: Nature communications
Published: July 29, 2024
Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon system.
Journal: Antiviral research
Published: July 24, 2024
PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2.
Journal: bioRxiv : the preprint server for biology
Published: April 25, 2024
An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals.
Journal: Scientific reports
Published: April 16, 2024
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system.
Journal: Science advances
Published: December 21, 2022
An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals.
Journal: iScience
Published: April 21, 2022
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro.
Journal: Antimicrobial agents and chemotherapy
Published: June 07, 2021
In vitro efficacy of artemisinin-based treatments against SARS-CoV-2.
Journal: Scientific reports
Published: October 06, 2020
Showing 1-11 of 11
Last Updated: 09/26/2026